Supplementary Table 1: Comparison of characteristics for patients with matching score <50% versus ≥50% and first versus second line or greater.

Characteristics	Matching Score <50% (N = 7)	Matching Score ≥50% (N = 11)	P value
Age > 67 years* (N (%))	3 (42.8%)	6 (54.5%)	1.0
Number of men (N (%))	3 (42.9%)	4 (36.4%)	1.0
Matched therapy as first line therapy (N (%))	1 (14.2%)	4 (36.4%)	0.60
	1st line of therapy	**Later lines**	
Matching score ≥ 50%	4/5 (80%)	7/13 (54%)	0.3

*Age 67 was the median age of the overall cohort.

Supplementary Table 2: Molecular alterations and agents administered for 13 patients who did not achieve clinical benefit

Molecular alterations	**Drugs Administered**	**Matching Score (%) ≥50% versus <50%**
CDKN2A alteration *KRASG12V* *TP53* mutation	Palbociclib and trametinib	≥50%
CDKN2A alteration GNASR201H KRAS G12D TP53 mutation	Palbociclib and trametinib	≥50%
CDKN2A alteration *ERBB2* amplification *KRAS G12D*	Palbociclib and trametinib	≥50%
CDKN2A alteration *GNASR201C* *KRAS Q61H* *SMAD4* alteration	Palbociclib and trametinib	≥50%
Alterations in *CDKNA, CCND1, CCNE1, KRAS*	Palbociclib, trametinib, and bevacizumab	≥50%
Alterations in *CDKN2A, KRAS, TP53*	Palbociclib, trametinib, and bevacizumab	≥50%
MDM2 amplification Alterations in *AKT2, AXL, KRAS, TP53,*	Trametinib and everolimus	<50%
CDKNA loss Alterations in *BRCA2,* *IRS2, KRAS. SMAD4, TP53*	Olaparib and trametinib	<50%
Alterations in *BRCA1, KRAS, MEN1, MSH6*	Oxaliplatin* and capecitabine	<50%
CDKNA loss Alterations in *ARID1A, BRCA1, CDKN1B, ERBB2,* *KRAS, TP53*	Olaparib	<50%
Alteration in *ATM, CCND2, CDH1, FGFR2, FGF23,* *GNAS, MYC, NOTCH1, SMAD4, TP53*	Erlotinib, cetuximab, palbociclib, and trametinib	<50%
Alterations in *CDK4, CDKN2A, ERBB2, ERBB3, GLi1, KRAS, TP53*	Trastuzumab and pertuzumab	<50%
BRAF V600E Alterations in *CDH1, TP53,*	Trametinib and erlotinib	<50%

*Platinum agents target DNA repair and hence were considered as matched targeted agents for *BRCA*-mutant tumors

Supplementary Figure 1: Consort Diagram: A total of 123 patients with pancreatic cancer had NGS results in the database.